Lookie 👀 at what I got in the mail Joshua Starmer Can’t wait to get started!

Tail Risk / risk of "blowing up" a la Nassim Nicholas Taleb must be considered. LDR brachy for prostate per ASCENDE shows risk of death in 2 pts and these sound like horrible deaths! Debilitating pain + MI/PE in 1 pt and Fournier gangrene in another. I don't believe this is worth it for bPFS

Great article regarding surrogate endpoints. Drugs that initially had an increase in PFS in early studies were found decrease OS in later studies (see Table 1). ascopubs.org/doi/full/10.12…

Our inaugural paper, our manifesto is now out in The Lancet Oncology . This paper describes our mission, vision, and guiding principles. We also now invite you all to join our movement- our website is now live. thelancet.com/journals/lanon…

Excellent article on how studies have inappropriately calculated “improvement” in OS when it’s a 2nd endpoint and how to lookout for and fix this issue. ascopubs.org/doi/full/10.12…

Great paper by Andrew Vickers and Hoping to return one day Caution is needed when making Causal Inference... bjui-journals.onlinelibrary.wiley.com/doi/epdf/10.11…

Does anybody know the gr4 rate for prostate? 0415 only 1 gr4 and PACE-B had 0. 10 patients with Gr4 w/protons. A little less gr 1-3 toxicity but a higher risk of Gr4 toxicity - Doesn’t seem worth it. The paper below states Gr4 should be a “zero event” but still calls H+ safe 🤔

"Black swan events" (eg change in supervision req's) & decline in medicare population also likely to depress demand side. Per excellent discussion by Chirag Shah residency contraction may be needed to better match supply & demand

Fantastic new paper on sample size requirements of statistical models vs. #MachineLearning , except for not giving proper emphasis to smooth calibration curves: onlinelibrary.wiley.com/doi/10.1002/si… #Statistics

I love this type of innovation and research. Bold and different. Kudos Bill Loo MD PhD ⚡️☢️

Be on the look out, lest we get left behind...

Dr. David Palma Abdulaziz AlGhamdi I believe the results or ORATOR and ORATOR2, but none of my surgical friends do

This is especially true of medical journals. I still have to read a lot but am selective in what I read.

Crazy how Twitter lets us look at these back and forth arguments from these renowned experts! I highly recommend going through these threads - guaranteed to make you smarter 🧠 Stephen John Senn Frank Harrell Judea Pearl

PhilosopherMD Nadeem Riaz C. Jillian Tsai, MD, PhD Nancy Lee I know a lot of people that thought it was kinda nuts it became category 1 NCCN off a tiny single arm study. Pointing out that things were done poorly in another subsection of oncology is not a good argument for doing another thing poorly.

Our review on Multiplicity in Clinical Trials is now out in the Red Journal, with NRG Oncology Stephanie Pugh, John Park VA Kansas City, John Kang Kuan G. Sakthivel #radonc #stats redjournal.org/article/S0360-…

PhilosopherMD ♕Deborah Mayo♕ Frank Harrell M. Bolton Amit Chowdhry, MD, PhD NRG Oncology VA Kansas City John Kang Kuan G. Sakthivel We're all on bluesky having fun again. Come on. There is a sketch of the four major theories of inference here. errorstatistics.com/wp-content/upl…

Frank Harrell PhilosopherMD M. Bolton Amit Chowdhry, MD, PhD NRG Oncology VA Kansas City John Kang Kuan G. Sakthivel This is the limb-sawing logic of those who don't understand how conditionals work in reductio arguments errorstatistics.com/2017/04/15/if-…

Really a fantastic book. Highly recommend!

Biology has more data than ever before. We need to focus on interpreting these data. On the logical connections & the supportable conclusions. Falsifiable models can lead to reliable models.